Atorable EZ Tablet combines Atorvastatin 10 mg, an HMG-CoA reductase inhibitor, with Ezetimibe 10 mg, a cholesterol absorption inhibitor, to provide comprehensive lipid-lowering therapy. This dual mechanism reduces LDL cholesterol and total cholesterol, while supporting cardiovascular risk reduction.
Belonging to the cardiology and lipid-lowering segment, Atorable EZ is prescribed for patients with hypercholesterolemia, mixed dyslipidemia, and high cardiovascular risk. It is especially effective when monotherapy alone is insufficient to achieve target lipid levels.
The combination therapy improves patient compliance by providing two synergistic agents in a single tablet, reducing pill burden while ensuring consistent cholesterol management.
For PCD pharma franchise partners, distributors, exporters, and third-party manufacturers, Atorable EZ Tablet offers a profitable B2B opportunity, catering to hospitals, clinics, and specialty pharmacies across India, with high and recurring demand in the cardiovascular therapy market.